Research Topics
| MARY CROWSummaryAffiliation: Hospital for Special Surgery Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Interferon-alpha in systemic lupus erythematosusMary K Crow
Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
Curr Opin Rheumatol 16:541-7. 2004....
Trait-stratified genome-wide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosusSilvia N Kariuki
University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
Arthritis Res Ther 12:R151. 2010..These two heritable risk factors are shared between ancestral backgrounds. The aim of the study was to detect genetic factors associated with autoantibody profiles and serum IFN-α in SLE...- Regulation of CD40 ligand expression in systemic lupus erythematosusM K Crow
Department of Medicine, Hospital for Special Surgery and Weill Medical College of Cornell University, New York City, New York, USA
Curr Opin Rheumatol 13:361-9. 2001..More complete characterization of the mechanisms that regulate the magnitude and duration of CD40L expression should suggest new approaches to modulate this promising therapeutic target... - Developments in the clinical understanding of lupusMary K Crow
Autoimmunity and Inflammation Program, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA
Arthritis Res Ther 11:245. 2009..Nonetheless, progress in understanding the underlying immunopathogenesis of lupus and its impact on clinical disease has accelerated the pace of clinical research to improve the outcomes of patients with systemic lupus erythematosus... - Academic rheumatology: not just a man's worldMary K Crow
Mary Kirkland Center for Lupus Research, and Hospital for Special Surgery and Weill Medical College of Cornell University, New York, New York 10021, USA
Arthritis Rheum 52:694-6. 2005 - Anticyclic citrullinated peptide antibody-negative rheumatoid arthritis: clues to disease pathogenesisMary K Crow
Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA
Curr Rheumatol Rep 10:165-7. 2008 - Interferon pathway activation in systemic lupus erythematosusMary K Crow
Hospital for Special Surgery, New York, NY 10021, USA
Curr Rheumatol Rep 7:463-8. 2005..In addition, investigations of the mechanisms of induction of IFN pathway activation are suggesting clues to the triggers of autoimmunity in SLE... - Type I interferon in systemic lupus erythematosusM K Crow
Autoimmunity and Inflammation Program, Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA
Curr Top Microbiol Immunol 316:359-86. 2007.... - Mentors and heroes: the foundation and future of rheumatologyMary K Crow
Hospital for Special Surgery, New York, New York 10021, USA
Arthritis Rheum 56:1037-43. 2007 - Modification of accessory molecule signalingMary K Crow
Mary Kirkland Center for Lupus Research, Department of Medicine, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA
Springer Semin Immunopathol 27:409-24. 2006..Further elucidation of the complexities of members of the accessory molecule families and their functions should lead to an ever greater capacity for therapeutic modulation of the immune response in autoimmune and inflammatory diseases... 
Long interspersed nuclear elements (LINE-1): potential triggers of systemic autoimmune diseaseMary K Crow
Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York 10021, USA
Autoimmunity 43:7-16. 2010..Induction of type I IFN by L1-enriched nucleic acids through TLR-independent pathways could represent a first step in the complex series of events leading to systemic autoimmune disease...- Interferon-alpha: a therapeutic target in systemic lupus erythematosusMary K Crow
Mary Kirkland Center for Lupus Research, Rheumatology Division, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA
Rheum Dis Clin North Am 36:173-86, x. 2010..Meanwhile, promising clinical trials are moving forward to test the safety and efficacy of monoclonal antibody inhibitors of IFN-alpha. Other therapeutic approaches to target the IFN pathway may follow close behind... - Costimulatory molecules and T-cell-B-cell interactionsMary K Crow
Mary Kirkland Center, for Lupus Research, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA
Rheum Dis Clin North Am 30:175-91, vii-viii. 2004..Knowledge of the structure and function of these costimulatory molecules can be used to manipulate immune function and inhibit autoimmunity and inflammation in the setting of disease... - Microarray analysis of interferon-regulated genes in SLEMary K Crow
Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, 535 East 70th Street, New York, NY, USA
Autoimmunity 36:481-90. 2003..Definition of the nature of the major IFNs, or other factors, that drive the IFN-regulated gene expression signature noted in SLE is an important area for investigation that may lead to new approaches to targeted therapy of SLE... - Type I interferon in organ-targeted autoimmune and inflammatory diseasesMary K Crow
Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, Weill Cornell Medical College, 535 East 70th Street, New York, NY 10021, USA
Arthritis Res Ther 12:S5. 2010.... - Type I interferon and autoimmune diseaseMary K Crow
Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY, USA
Autoimmunity 36:445-6. 2003 - Studies of autologous T cell activation in the Kunkel laboratoryM K Crow
The Mary Kirkland Center for Lupus Research, Rheumatology Research Program, Hospital for Special Surgery, New York, NY 10021, USA
Lupus 12:163-9. 2003.... 
Microarray analysis of gene expression in lupusMary K Crow
Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY, USA
Arthritis Res Ther 5:279-87. 2003....- Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodiesJing Hua
Mary Kirkland Center for Lupus Research and Department of Medicine, Hospital for Special Surgery, and Weill Medical College of Cornell University, New York, New York 10021, USA
Arthritis Rheum 54:1906-16. 2006..These data provide additional support for the view that IFNalpha mediates immune system activation and dysregulation in SLE... - Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohortClio P Mavragani
Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, USA
Arthritis Rheum 62:392-401. 2010..Since an interferon (IFN) signature is variably expressed among RA patients, we investigated whether plasma type I IFN activity might predict the response to TNF antagonist therapy... - Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trialRobert F Spiera
Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA
Ann Rheum Dis 70:1003-9. 2011..To assess the safety and effectiveness of imatinib mesylate in the treatment of diffuse cutaneous systemic sclerosis (dcSSc)... - Activation of type I interferon in systemic lupus erythematosusKyriakos A Kirou
Assistant Professor of Clinical Medicine and Assistant Scientist, Mary Kirkland Center for Lupus Research, Department of Medicine, Hospital for Special Surgery and Weill Medical College of Cornell University, 535 East 70th Street, New York, NY 10021, USA
Expert Rev Clin Immunol 3:579-88. 2007..First, IFN may be a useful biomarker of disease subtype and activity and, second, IFN is a rational target for therapeutic intervention. Cautious blockade of this pathway might eliminate an important contributor to autoimmunity... - Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active diseaseKyriakos A Kirou
Mary Kirkland Center for Lupus Research, Hospital for Special Surgery and Weill Medical College of Cornell University, New York, New York, USA
Arthritis Rheum 52:1491-503. 2005..This study examined the hypothesis that increased disease severity and activity, as well as distinct autoantibody specificities, characterize SLE patients with activation of the type I IFN pathway... - Distinct inflammatory gene pathways induced by particlesAndrew D Pearle
Shoulder and Sports Medicine Service, Hospital for Special Surgery, New York, NY 10021, USA
Clin Orthop Relat Res 458:194-201. 2007..The induction of T cell activation by titanium particles suggests lymphocytes may contribute to the inflammation that mediates osteolysis in patients with metallic particulate debris after total joint replacement... - Measurement of cytokines in autoimmune diseaseKyriakos A Kirou
Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY, USA
Methods Mol Med 102:129-54. 2004..Detailed methods are provided for these assays... - Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosusMary J Roman
Division of Cardiology, Weill Medical College of Cornell University, The Hospital for Special Surgery, New York, NY 10021, USA
N Engl J Med 349:2399-406. 2003.... - Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanerceptClio P Mavragani
Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA
Arthritis Rheum 56:3995-4004. 2007..To address the hypothesis that tumor necrosis factor blockade can result in increased levels of interferon-alpha (IFNalpha) and BAFF, we quantified those mediators in plasma from etanercept- and placebo-treated SS patients... - Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosusKyriakos A Kirou
Hospital for Special Surgery, and Weill Medical College of Cornell University, New York, New York 10021, USA
Arthritis Rheum 50:3958-67. 2004..CONCLUSION: The coordinate activation of IFNalpha-induced genes is a characteristic of PBMCs from many SLE patients, supporting the hypothesis that IFNalpha is the predominant stimulus for IFIG expression in lupus... - Arterial stiffness in chronic inflammatory diseasesMary J Roman
Division of Cardiology, Weill Medical College, Cornell University, 525 East 68th St, New York, NY 10021, USA
Hypertension 46:194-9. 2005.... - Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradationDavid R Fernandez
Division of Rheumatology, Department of Medicine, State University of New York, Syracuse, NY 13210, USA
J Immunol 182:2063-73. 2009..The results suggest that activation of mTOR causes the loss of TCRzeta in lupus T cells through HRES-1/Rab4-dependent lysosomal degradation... - Preclinical carotid atherosclerosis in patients with rheumatoid arthritisMary J Roman
Division of Cardiology, Weill Medical College of Cornell University, Hospital for Special Surgery, and The Rogosin Institute, New York, New York 10021, USA
Ann Intern Med 144:249-56. 2006..Rheumatoid arthritis is associated with increased morbidity and mortality because of cardiovascular disease, independent of traditional risk factors... - Relationship of asymmetric dimethylarginine and homocysteine to vascular aging in systemic lupus erythematosus patientsMichelle Perna
Weill Cornell Medical College and Hospital for Special Surgery, New York, New York 10021, USA
Arthritis Rheum 62:1718-22. 2010..The aim of this study was to assess the relationship of ADMA and homocysteine to subclinical vascular disease in patients with SLE... - Ongoing immunoglobulin class switch DNA recombination in lupus B cells: analysis of switch regulatory regionsShiquan Liu
Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY 10021, USA
Autoimmunity 37:431-43. 2004..These results support a role for exogenous signals, such as through CD40 ligation, rather than altered genomic sequence, in the increased production of class switched autoantibodies in SLE... - Soluble mediators as therapeutic targets in systemic lupus erythematosus: cytokines, immunoglobulin receptors, and the complement systemKyriakos A Kirou
Weill Medical College of Cornell University, New York, NY, USA
Rheum Dis Clin North Am 32:103-19, ix. 2006.... - Rate and determinants of progression of atherosclerosis in systemic lupus erythematosusMary J Roman
Weill Medical College of Cornell University, and the Hospital for Special Surgery, New York, New York 10021, USA
Arthritis Rheum 56:3412-9. 2007..To determine the rate of atherosclerosis progression as well as the relationship of traditional risk factors, systemic lupus erythematosus (SLE)-related factors, and treatment to atherosis progression in SLE patients... - Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosusAfshin Farzaneh-Far
Hospital for Special Surgery, Weill Medical College of Cornell University, New York, New York 10021, USA
Arthritis Rheum 54:3918-25. 2006..However, in this population, they are not associated with evidence of myocardial hypertrophy, systolic dysfunction, coronary or carotid atherosclerosis, or other vascular abnormalities... - T cell proliferation induced by autologous non-T cells is a response to apoptotic cells processed by dendritic cellsAnna D Chernysheva
Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, Weill Medical College and Graduate School of Medical Sciences of Cornell University, New York, NY 10021, USA
J Immunol 169:1241-50. 2002..Induction of an in vivo autologous mixed lymphocyte reaction by caspase-modified self-Ags present in apoptotic cells may represent a mechanism to maintain peripheral immune tolerance... - Systemic lupus erythematosus predicts increased left ventricular massJanice Pieretti
Division of Cardiology, Weill Medical College of Cornell University and the Hospital for Special Surgery, New York, NY 10021, USA
Circulation 116:419-26. 2007..Whether SLE alters left ventricular (LV) structure and function in the absence of valvular and clinical coronary artery disease is unknown... - Innate immune system activation in osteoarthritis: is osteoarthritis a chronic wound?Carla R Scanzello
Hospital for Special Surgery, Division of Rheumatology, New York, New York, USA
Curr Opin Rheumatol 20:565-72. 2008..In this report, we review evidence that certain extracellular matrix components of joint tissues (hyaluronan and fibronectin) may act as TLR stimuli, and summarize recent literature implicating TLR activation in osteoarthritis... - Independent association of rheumatoid arthritis with increased left ventricular mass but not with reduced ejection fractionRebecca L Rudominer
Weill Cornell Medical College, New York, New York 10021, USA
Arthritis Rheum 60:22-9. 2009..This study was undertaken to investigate whether RA is associated with underlying structural and functional abnormalities of the left ventricle (LV)... - Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseasesAndreas Goules
Department of Pathophysiology, School of Medicine, National University of Athens, 75 M. Asias Street, 11527 Athens, Greece
J Autoimmun 26:165-71. 2006..Soluble CD40L is elevated in sera of SS and SLE patients but further investigation is needed to determine its possible role in SLE nephritis and Sjögren's syndrome... - Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patientsTimothy B Niewold
University of Chicago, Section of Rheumatology, Chicago, IL 60637, USA
Arthritis Rheum 58:2481-7. 2008..The aim of this study was to determine whether the IRF5 SLE risk haplotype mediates the risk of SLE by predisposing patients to the development of high levels of serum IFNalpha activity... - Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGEJane Tian
Inflammation and Autoimmune Group, Research Department, MedImmune, Gaithersburg, Maryland 20878, USA
Nat Immunol 8:487-96. 2007..Our data demonstrate a mechanism by which HMGB1 and RAGE activate plasmacytoid dendritic cells and B cells in response to DNA and contribute to autoimmune pathogenesis... - Characterization of human complement receptor type 2 (CR2/CD21) as a receptor for IFN-alpha: a potential role in systemic lupus erythematosusRengasamy Asokan
Department of Medicine and Department of Immunology, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Denver, CO 80262, USA
J Immunol 177:383-94. 2006.... - Age- and sex-related patterns of serum interferon-alpha activity in lupus familiesTimothy B Niewold
Section of Rheumatology, University of Chicago, Chicago, Illinois 60637, USA
Arthritis Rheum 58:2113-9. 2008..The purpose of this study was to determine whether serum IFNalpha activity in SLE patients and their healthy first-degree relatives is highest in early adulthood, when the incidence of SLE is greatest... - Serum type I interferon activity is dependent on maternal diagnosis in anti-SSA/Ro-positive mothers of children with neonatal lupusTimothy B Niewold
University of Chicago, Section of Rheumatology, Chicago, Illinois 60637, USA
Arthritis Rheum 58:541-6. 2008.... - Collaboration, genetic associations, and lupus erythematosusMary K Crow
N Engl J Med 358:956-61. 2008 - Early growth response-1 is required for CD154 transcriptionRandy Q Cron
Division of Rheumatology, Children s Hospital of Philadelphia, PA 19104, USA
J Immunol 176:811-8. 2006..This has implications for selective targeting of Egr family members to control abnormal expression of CD154 in autoimmune diseases such as systemic lupus erythematosus... - Interferon-alpha: a new target for therapy in systemic lupus erythematosus?Mary K Crow
Arthritis Rheum 48:2396-401. 2003 - Fast forward for systemic lupus erythematosus clinical trialsMary K Crow
Nat Clin Pract Rheumatol 4:387. 2008
Research Grants
- Interferon in Systemic Lupus ErythematosusMary K Crow; Fiscal Year: 2010..Elucidation of this important pathway should lead to more targeted modulation of disease mediators in systemic autoimmune diseases. ..
- Interferon in Systemic Lupus ErythematosusMARY CROW; Fiscal Year: 2009..Elucidation of this important pathway should lead to more targeted modulation of disease mediators in systemic autoimmune diseases. ..
- RHEUMATOLOGY RESEARCH TRAINING PROGRAMMARY CROW; Fiscal Year: 2007..Support is requested for 3 MD, MD-PhD, or PhD trainees who will gain the skills required to make important advances in the health of patients with rheumatic disease. ..
- Interferon in Systemic Lupus ErythematosusMARY CROW; Fiscal Year: 2007..Elucidation of this important pathway should lead to more targeted modulation of disease mediators in systemic autoimmune diseases. ..
- Premature Atherosclerosis in Rheumatic DiseasesMARY CROW; Fiscal Year: 2006..abstract_text> ..
- Identification of Rheumatic Disease GenesMARY CROW; Fiscal Year: 2004..abstract_text> ..
- Fourth Biennial Arthritis Research ConferenceMARY CROW; Fiscal Year: 2003..abstract_text> ..
- CD40 LIGAND IN SYSTEMIC LUPUS ERYTHEMATOSUSMARY CROW; Fiscal Year: 2002..These studies should elucidate disease pathogenesis and identify new targets for therapy in SLE. ..